New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
07:49 EDTSNSSSunesis risk/reward attractive at current levels, says Leerink
Leerink views the risk/reward for shares of Sunesis as very attractive at current levels and reiterates an Outperform rating on the stock. The firm upped its price target for shares to $14 from $10.
News For SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
16:04 EDTSNSSSunesis Chief Medical Officer Adam Craig to step down at end of year
Subscribe for More Information
16:03 EDTSNSSSunesis to submit MAA for vosaroxin with EMA by end of 2015
Sunesis Pharmaceuticals announced that the company intends to submit a Marketing Authorization Application for vosaroxin as a treatment for acute myeloid leukemia with the European Medicines Agency by the end of 2015. The company recently announced that it met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guidance to the company through the MAA process. Based on these discussions, the company is proceeding with an MAA filing for the indication of relapsed/refractory AML in patients age 60 years and older, a population with the greatest medical need and for whom the greatest benefit was observed in the vosaroxin/cytarabine treatment arm of VALOR, the company's pivotal Phase 3 study of vosaroxin and cytarabine in adult patients with relapsed or refractory AML.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use